Thesis
VAX-31's 31-valent pneumococcal vaccine thesis hinges on Phase 3 non-inferiority and superiority data against Prevnar 20 and Capvaxive
VAX-31 is a 31-valent pneumococcal conjugate vaccine targeting invasive pneumococcal disease and pneumonia in adults, with all three Phase 3 OPUS trials now fully enrolled across 6,191 participants. The thesis resolves on whether OPUS-1 topline data demonstrate non-inferiority to Prevnar 20 and Capvaxive across shared serotypes with superiority on incremental serotypes, enabling a BLA submission. The primary competitive risk is Pfizer's Prevnar 20 and Merck's Capvaxive, which hold established formulary positions and prescriber inertia that a superior serotype profile alone may not displace.
Focus
Remaining Phase 3 studies data announcement
H1 2027
Bull
A positive outcome would show VAX-31 meeting non-inferiority criteria across all 20 shared serotypes versus Prevnar 20 and Capvaxive, while achieving statistically significant superiority on the 11 incremental serotypes unique to VAX-31, replicating and extending the Phase 1/2 OPA signal published in The Lancet Infectious Diseases. This would validate the 31-valent breadth advantage as clinically meaningful, de-risk the BLA pathway supported by Breakthrough Therapy designation, and establish a compelling differentiation story against all approved competitors.
Bear
The primary failure mode is VAX-31 missing non-inferiority thresholds on one or more of the 20 shared serotypes — particularly the lower-immunogenicity serotypes where higher-valency conjugate vaccines have historically struggled with immunological interference. A secondary risk is that superiority on incremental serotypes is demonstrated numerically but fails to reach statistical significance in OPUS-1's powered comparisons, undermining the differentiation narrative against Capvaxive (PCV21, Merck) and blunting the commercial case for switching.
Unlock the full thesis for PCVX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.